Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgery
NCT06780202Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in foot disorders, ankle injuries and disorders and Achilles tendon injury comparing Medrol with Standard of Care (2 arms). Primary endpoints: Postoperative Nausea at 7 days, Postoperative Pain at 6 months and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
foot disordersankle injuries and disordersAchilles tendon injury
Beyond the preview
Go deeper on NCT06780202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780202.